HM
MLTX icon

HealthCor Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

HealthCor Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-60,027
Closed -$613K – 94
2021
Q1 		$613K Buy
+60,027
New +$662K 0.02% 80

Other funds holding MLTX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HealthCor Management's MLTX Position: Q2 2021 in Review

HealthCor Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2021, closing a stake of 60,027 shares — an estimated $613K sold.

HealthCor Management first reported a position in MLTX in Q1 2021 and held it in 1 quarter. The position peaked at $613K in Q1 2021. 46 funds tracked by Wall St. Rank hold MLTX as of Q2 2021.

  • HealthCor Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2021 after selling out during the quarter.
  • HealthCor Management sold 60,027 MoonLake Immunotherapeutics shares in Q2 2021, an estimated $613K.
  • HealthCor Management first reported a position in MoonLake Immunotherapeutics in Q1 2021 and held it in 1 quarter.
  • HealthCor Management's MoonLake Immunotherapeutics position peaked at $613K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2021.

Based on HealthCor Management's 13F filing for Q2 2021, filed 16 Aug 2021.